Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation.
We evaluated the prognostic role of 18FDG-PET performed before ASCT in patients affected by lymphoma who underwent high-dose chemotherapy followed by ASCT as first-line treatment for high-risk disease or as second-line or more for relapsed or refractory disease. We retrospectively analyzed 53 consecutive patients, 14 with Hodgkin Lymphoma (HL) and 39 with non-Hodgkin Lymphoma (NHL), treated between February 1999 and October 2006 at our institution, who had a pre-ASCT FDG-PET (pPET) evaluation. Median age was 45 years (range: 18-69). After a median follow-up of 31 months (range: 8-91), 7 out of 16 pPET+ patients and 10 out of 37 pPET- patients experienced lymphoma relapse. The 5-year OS is 90% and 55% (p = 0.01) in patients with negative and positive pPET, respectively. In conclusion, a positive pPET indicates a poorer outcome after ASCT with respect to a negative pPET; this subset of patients should be considered candidate to more intensive or investigational approaches.
Crocchiolo
Roberto
R
Hematology and BMT Unit, Department of Oncology, San Raffaele Scientific Institute, Milano, Italy. crocchiolo.roberto@hsr.it
Canevari
Carla
C
Assanelli
Andrea
A
Lunghi
Francesca
F
Tassara
Michela
M
Stanghellini
Maria Lupo
ML
Clerici
Daniela
D
Landoni
Claudio
C
Servida
Paolo
P
Bernardi
Massimo
M
Peccatori
Jacopo
J
Ferreri
Andres
A
Gianolli
Luigi
L
Bordignon
Claudio
C
Caligaris-Cappio
Federico
F
Ciceri
Fabio
F
Fazio
Ferruccio
F
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019788:Fluorodeoxyglucose F18; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods*; D011300:Preoperative Care; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies; D015996:Survival Rate; D014182:Transplantation, Autologous
D019788:Fluorodeoxyglucose F18